Journal article icon

Journal article

Dupilumab efficacy and safety in moderate-to-severe uncontrolled Asthma

Abstract:

Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma.We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or matched-volume placebos for 52 weeks. The primary end points were the annualized rate of severe a...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/nejmoa1804092

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Target Discovery Institute
Oxford college:
St Edmund Hall
Role:
Author
ORCID:
0000-0002-4288-5973
Expand authors...
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
378
Issue:
26
Pages:
2486-2496
Publication date:
2018-06-28
Acceptance date:
2018-04-26
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Pmid:
29782217
Source identifiers:
854634

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP